Source: Rheumetology Network Author: Katie Robinson Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc)
Of the whole study group (RA and SLE), 54% used hydroxychloroquine and 44% had QTc lengths of more than 440 milliseconds. They found that the adjusted QTc length among hydroxychloroquine users was comparable to those who did not use the drug.
Source: Journal of Marine Medical Society Date of Submission 23-Aug-2020 Date of Decision 18-Sep-2020 Date of Acceptance 29-Sep-2020 Date of Web Publication 06-Nov-2020 Correspondence Address:Vivek
Figure 3 reported random forest for 10 studies comparing HCQ+AZM. Use of the combination HCQ+AZM was associated with 25% lower mortality risk
Source: HCQmeta.com • HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 132 studies to date is
Professor Raoult had very quickly sent a “warning letter” to the newspaper about this study which seemed to him incomplete and including too much bias.
WMA DECLARATION OF HELSINKI – ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS
This means that zinc, low dose HCQ, and azithromycin and may prevent a large number of hospitalizations and probably deaths during the SARS-CoV-2 pandemic.
We found a higher survival rate in patients treated with hydroxychloroquine and with macrolides in our study.
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 115 studies to date is estimated to be 1 in 20 million (p = 0.000000049).
This study of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Mexico demonstrated that age and CRP levels upon ICU admission were associated with in-hospital mortality
Our results can assure that hydroxychloroquine used for COVID-19 patients is safe, highly tolerable, and with minimum side effects.
The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients.
Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement.
HCQ has greater efficacy if given earlier in the course of the disease. Several negative studies have been withdrawn due to methodological improprieties.
Hydroxychloroquine had a modest effect on hospital length stay and days in ICU compared with Standard Care.
Our findings indicate that Hydroxychloroquine can be an effective agent in postexposure prophylaxis.
Source: MedRxiv. Full Study in PDF here Xabier Garcia-Albeniz, Julia Del Amo, Rosa Polo, Jose Miguel Morales Asencio, Miguel A HernanmedRxiv 2020.09.29.20203869; doi: https://doi.org/10.1101/2020.09.29.20203869 Abstract Background: There is disagreement about whether hydroxychloroquine (HCQ) is effective as prophylaxis
In our study, we found hydroxychloroquine wasn’t associated with significant arrhythmia clearly relating to hydroxychloroquine so it seemed the drug was very, very safe
Hydroxychloroquine seems to be safe, regardless of the clinical setting in which it is started, so long as an adequate ECG monitoring strategy is in place.
There is little reason to continue demonizing a drug for political reasons while the nation is desperately searching for an end to lockdowns, quarantines, masks, and fear of a disease that can be treated.
Therefore, Hydroxychloroquine is considered as the first‐line of COVID-19 treatment.
Source: Longdom.org ABSTRACT Coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) calls for unprecedented measures to control the spread
Source: The Guardian Author: Melissa Davey One of the world’s leading medical journals, the Lancet, has reformed its editorial policies following a shocking case of
These results are evidences to support the early use of HCQ in post exposure prophylaxis.
To have covered up the knowledge for four decades that viruses could potentially be treated by antimicrobials required extensive effort
Source: The Lancet Summary Background Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
In this trial, no deaths occurred related to hydroxychloroquine, and serious side effects were rare.
Source: MedRxiv View ORCID ProfileSARAH M LOFGREN, View ORCID ProfileMelanie R Nicol, Ananta S Bangdiwala, View ORCID ProfileKatelyn A Pastick, View ORCID ProfileElizabeth C Okafor, View ORCID ProfileCaleb P Skipper, View ORCID ProfileMatthew F Pullen, View ORCID ProfileNicole W Engen, View
An Urgent Call to Depoliticize Medicine in the COVID-19 Pandemic
Source: American Institute for Economic Research The following letter has made an impact on public health authorities not only in Belgium but around the world. The text
Ms Lobb, is about two-thirds of the way through her four month trial and there have been no side effects so far. She also hasn’t contracted COVID-19.
Source: KUSI News. EL CENTRO (KUSI) – A doctor in El Centro said he has treated almost 1,700 COVID-19 patients with Hydroxychloroquine, Z pac, and
Source: Taylor & Francis Online Eleni Karatza, George Ismailos, Markos Marangos & Vangelis Karalis (2020) Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients’ characteristics: a review
Source: Pan African Medical Journal Mary Eyram Ashinyo1,&, Vida Duti2, Stephen Dajaan Dubik3, Kingsley Ebenezer Amegah4, Selorm Kutsoati5, Ebenezer Oduro-Mensah6, Peter Puplampu7, Martha Gyansa-Lutterodt8, Delese
Source: Sky News: Alan Jones Liberal MP Craig Kelly says studies have shown a 73 per cent reduction rate in mortality where Hydroxychloroquine was dispensed
Source:Sky News Australia Liberal MP Craig Kelly reports that there has been study after study that shows that Hydroxychloroquine, when administered early, can “lower the
HCQ or CQ should be used efficiently alone or in combination with AZ to optimize the management of asymptomatic and mild cases of COVID-19.
Source: MedRxiv Tarek Sulaiman, View ORCID ProfileAbdulrhman Mohana, Laila Alawdah, Nagla Mahmoud, Mustafa Hassanein, Tariq Wani, Amel Alfaifi, Eissa Alenazi, Nashwa Radwan, Nasser AlKhalifah, Ehab Elkady, Manwer AlAnazi, Mohammed Alqahtani, Khalid Abdalla, Yousif Yousif, Fouad AboGazalah, Fuad Awwad, Khaled AlabdulKareem, Fahad AlGhofaili, Ahmed AlJedai, Hani Jokhdar, Fahad Alrabiah doi: https://doi.org/10.1101/2020.09.09.20184143 Abstract ABSTRACT BACKGROUND: Currently, there is no proven effective therapy nor vaccine for the treatment of SARS-CoV-2. Evidence regarding
Source: Mahidol Oxford Tropical Medicine Research Unit As the world waits impatiently for a COVID-19 vaccine, an exhaustive review of hydroxychloroquine and chloroquine pharmacology suggests
